Dr. Baskin-Bey is an international oncology biopharmaceutical veteran with more than 20-years’ experience in academia and industry. Previously, she was Chief Medical Officer and Executive Board Member of Nanobiotix, an intratumoral nanomedicine company. Prior to that, Dr. Baskin-Bey was Chief Medical Officer of Innocrin Pharmaceuticals, a biotech focused on androgen biosynthesis inhibition for the treatment of solid tumors. Dr. Baskin-Bey joined Innocrin from Janssen Oncology (Johnson & Johnson), where she led both early- and late-stage oncology global development programs for newly in- licensed products. Precursory to that, whilst based in the EU, she was responsible for drug launch and life-cycle management of several large global oncology programs as well as Head of European Medical Affairs for Astellas Pharma.

Dr. Baskin-Bey received a bachelor’s degree in Chemistry from Hunter College, NY, NY, and a medical degree from Mount Sinai/NYU School of Medicine, NY, NY. She was trained in general surgery and oncology at The Mayo Clinic, Rochester, MN; in clinical trial biostatistics from EORTC, Brussels, BE; in business leadership from INSEAD, Fontainebleau, FR; and in basic science research principles by the National Institutes of Health in Bethesda, MD.

Additionally, Dr. Baskin-Bey is the founder and president of The EGCC, a comprehensive global oncology consulting firm and concurrently, serves as a board member to Catalyst Clinical Research, an oncology- specialized Clinical Research Organization.

As Chief Medical Officer at Immunophotonics, she is supporting the development programs and implementation of the clinical corporate strategy.